Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.59 |
| ▸ | ALK | Q9UM73 | 8/20 | 0.54 |
| ▸ | INSR | P06213 | 7/20 | 0.54 |
| ▸ | IGF1R | P08069 | 7/20 | 0.54 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.52 |
| ▸ | CDC7 | O00311 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1044692 | 0.80 | CDK2 (0.55) | EGFRALKIGF1RCDC7GSK3B | |
| SCHEMBL969794 | 0.79 | EGFR (0.52) | EGFRALKINSRIGF1RPTK2 | |
| SCHEMBL15190332 | 0.78 | CDC7 (0.62) | EGFRALKCDC7GSK3BLRRK2 | |
| SCHEMBL1046847 | 0.78 | CDC7 (0.71) | EGFRCDC7GSK3BLRRK2 | |
| SCHEMBL30020501 | 0.77 | INSR (0.62) | EGFRALKINSRIGF1RPTK2 | |
| SCHEMBL30341887 | 0.75 | EGFR (1.00) | EGFRALKINSRIGF1RPTK2 | |
| SCHEMBL517288 | 0.75 | EGFR (1.00) | EGFRALKINSRIGF1RPTK2 | |
| SCHEMBL1043643 | 0.72 | CDC7 (0.62) | EGFRALKCDC7GSK3BLRRK2 | |
| SCHEMBL517495 | 0.72 | EGFR (0.85) | EGFRALKINSRIGF1RPTK2 | |
| SCHEMBL26087590 | 0.72 | ALK (0.73) | EGFRALKINSRIGF1RPTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2454257-B1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | ABBVIE INC (US) | 2013-08-21 | — | — | EP | claimed |
| US-8435980-B2 | Pyrrolopyridine inhibitors of kinases | ABBVIE INC. (US) | 2013-05-07 | — | — | US | claimed |
| EP-2454257-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | Abbott Laboratories (US) | 2012-05-23 | — | — | EP | claimed |
| WO-2011008915-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-01-20 | — | — | WO | claimed |
| US-20110015173-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-01-20 | — | — | US | claimed |
| EP-2454257-B1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | ABBVIE INC (US) | 2013-08-21 | — | — | EP | disclosed |
| US-8435980-B2 | Pyrrolopyridine inhibitors of kinases | ABBVIE INC. (US) | 2013-05-07 | — | — | US | disclosed |
| EP-2454257-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | Abbott Laboratories (US) | 2012-05-23 | — | — | EP | disclosed |
| WO-2011008915-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-01-20 | — | — | WO | disclosed |
| US-20110015173-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015173-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | CDC7, MAP3K7, CDK1 | EGFR 1635/4885ALK 1717/4885INSR 2692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.